MarketCap
Facebook
X
Telegram
Dyne Therapeutics Income Statement 2025-2011 | DYN
Brief overview of profit and loss at Dyne Therapeutics
The conclusions below are based on five years of reported results. Dyne Therapeutics reported revenue of 3 million dollars in 2012 and 506 million dollars by 2017. Across the full period, sales moved by +16766.7%; the average annual rate was 178.9%. The annual growth rate indicates an exceptionally strong top-line trend.
At the gross-profit level, the result moved from 3 million dollars to 1.9 billion dollars, a change of +63566.7%. Gross margin moved from 100% to 377.5%. Improving gross profitability strengthens the quality of revenue growth.
EBITDA changed from $740 million to $455 million (−38.5%). Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of 24666.7% and 89.9%. The business retained less EBITDA from each unit of revenue.
Net income changed from 87 million dollars to 76 million dollars (−12.6%). Lower net income weakens the overall financial picture.
Conclusion
The five-year picture requires weighing both strengths and weaknesses. The positive side is supported by sales growth and a stronger gross margin. The most visible risks are lower net income and a declining EBITDA margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Dyne Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.64 B | 1.34 B | 1.58 B | 816 M | 442 M | 134 M | - | - | - | - | - | - | - | 2.02 B | - |
Shares |
165 M | 102 M | 61.5 M | 55.6 M | 51.6 M | 6.92 M | - | - | - | - | - | - | - | 100 M | - |
Historical Prices |
16 | 13.1 | 25.7 | 14.7 | 8.57 | 18.5 | - | - | - | - | - | - | - | - | - |
Net Income |
-446 | -317 | -236 | -168 | -149 M | -59.4 M | -14.9 M | -4.81 M | 76 M | -1.24 B | 50 M | -67 M | -356 M | 87 M | -1.64 B |
Revenue |
- | - | - | - | - | - | - | - | 506 M | 1.37 B | 842 M | 1.47 B | 3 M | 3 M | 1.58 B |
Cost of Revenue |
86.5 M | 63.3 M | 48.9 M | 35.3 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | 1.91 B | 2.04 B | 1.84 B | 321 M | 321 M | 3 M | 622 M |
Operating Income |
-468 M | -344 M | -242 M | -171 M | -150 M | -58.6 M | -13.8 M | - | - | - | - | - | - | - | - |
Interest Expense |
22 M | 26.5 M | 6.22 M | 2.86 M | 734 K | -790 K | -1.03 M | - | - | - | - | - | - | - | - |
EBITDA |
-466 M | -342 M | -240 M | -169 M | -149 M | -57.9 M | -13.6 M | -4.77 M | 455 M | 126 M | 678 M | -26 M | 149 M | 740 M | 110 M |
Operating Expenses |
468 M | 344 M | 242 M | 171 M | 150 M | 58.6 M | 13.8 M | 4.8 M | 189 M | 161 M | 128 M | -308 M | 97 M | -81 M | 135 M |
General and Administrative Expenses |
69.9 M | 62.5 M | 31.4 M | 28.2 M | 28.7 M | 13.4 M | 2.79 M | 517 K | 189 M | 161 M | 128 M | -97 M | 97 M | -22 M | 135 M |
All numbers in USD currency
Quarterly Income Statement Dyne Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
166 M | 165 M | 143 M | 114 M | 114 M | 102 M | 102 M | 100 M | 87.1 M | 61.5 M | 61.3 M | 61 M | 58.3 M | 55.6 M | 51.9 M | - | 51.6 M | 51.6 M | 51.3 M | 51.2 M | 49.5 M | 45.1 M | 6.92 M | 2.71 M | 8.76 M | 2.59 M | 2.49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-179 M | -121 M | -108 M | -111 M | -115 M | - | -97.1 M | -65.1 M | -65.6 M | - | -60.2 M | -64.9 M | -44.2 M | - | -41.4 M | -52.3 M | -35.6 M | - | -42.6 M | -30 M | -25 M | - | -13.9 M | -8.98 M | -7.89 M | - | -14.9 M | -1.5 M | -2.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
28.8 M | 28.6 M | 22.5 M | 19.5 M | 20.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-182 M | -125 M | -114 M | -116 M | -122 M | - | -106 M | -72 M | -69.2 M | - | -62.3 M | -66.7 M | -45.5 M | - | -42.3 M | -52.8 M | -35.8 M | - | -42.8 M | -30.2 M | -25.1 M | - | -13.5 M | -8.68 M | -7.85 M | - | -3.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
3.1 M | 4.42 M | 2.9 M | 94 K | 7.01 M | - | 8.53 M | 6.86 M | 3.51 M | - | 2.06 M | 1.83 M | 1.28 M | - | 894 K | 451 K | 200 K | - | 184 K | 210 K | 166 K | - | -400 K | -307 K | -33 K | - | -2.24 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-181 M | -125 M | -113 M | -115 M | -122 M | - | -105 M | -71.6 M | -68.8 M | - | -61.9 M | -66.3 M | -45.1 M | - | -41.9 M | -52.3 M | -35.4 M | - | -42.5 M | -30 M | -24.9 M | - | -13.3 M | -8.48 M | -7.7 M | - | -3.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
182 M | 125 M | 114 M | 116 M | 122 M | - | 106 M | 72 M | 69.2 M | - | 62.3 M | 66.7 M | 45.5 M | - | 42.3 M | 52.8 M | 35.8 M | - | 42.8 M | 30.2 M | 25.1 M | - | 13.5 M | 8.68 M | 7.85 M | - | 3.63 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
29.5 M | 24.4 M | 16.7 M | 16.6 M | 15.9 M | - | 12.9 M | 9.7 M | 24.6 M | - | 7.02 M | 7.61 M | 7.93 M | - | 7.61 M | 6.09 M | 7.55 M | - | 6.26 M | 6.29 M | 6.51 M | - | 3.84 M | 1.34 M | 1.76 M | - | 647 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Dyne Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
China
Canada
USA
Bermuda
Brasil
Britain
India
Chile
Singapore
Argentina
Israel
